Jazz Pharmaceuticals plc — Director's Dealing 2022

Mar 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-03-01

Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-01	Ordinary Shares	M	9700	$46.83	Acquired	335488	Direct
2022-03-01	Ordinary Shares	S	3260	$135.7319	Disposed	332228	Direct
2022-03-01	Ordinary Shares	S	3041	$136.7288	Disposed	329187	Direct
2022-03-01	Ordinary Shares	S	200	$137.404	Disposed	328987	Direct
2022-03-02	Ordinary Shares	S	6000	$150.0	Disposed	322987	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-01	Non-Qualified Stock Option (right to buy)	$46.83	M	9700	Disposed	2022-08-08	Ordinary Shares (9700)	Direct

Footnotes

F1: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.18 to $136.12. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $136.18 to $137.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.255 to $137.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.